Radotinib (Supect)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Not currently approved in the United States.

Mechanism of action

From the NCI Drug Dictionary: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.

Diseases for which it is used

Also known as

  • Code name: IY5511HCl
  • Brand name: Supect